Biologics Process Development Inc. to Double the Size of its Bioprocess Laboratory
24 May 2011 - 11:12PM
Business Wire
VIROPRO (Pink Sheets: VPRO). Biologics Process
Development Inc. (“BPD”), a wholly-owned subsidiary of Viropro,
will double the size of its existing bioprocess- and scale-up
laboratory in Poway, CA.
BPD provides contract laboratory services for the biotechnology
and biopharmaceutical industry and specializes in molecular
biology, recombinant protein expression, cell culture, bacterial
fermentation, protein separation and purification, and frozen
cell/material storage.
BPD’s expansion enables the company to serve clients in need of
larger processing volumes, thereby also increasing its client
base.
Viropro also announces the appointment of Dr. Howard Levine and
Dr. Pete M. Fernandes to its Scientific Advisory Board.
Dr. Levine has over 30 years of experience in successful product
companies and as founder of BioProcess Technology Consultants,
Inc., the leading CMC consulting group in the biopharmaceutical
industry.
Prior to founding BioProcess Technology Consultants, Dr. Levine
was Vice-President of Manufacturing Operations at Repligen
Corporation, and previous to that, Director of Pilot Plant
Operations at Xoma Corporation. He has also held positions in
process development and manufacturing at Genentech and Amgen.
He holds a Ph.D. in chemistry from the University of Chicago and
completed a post-doctoral fellowship at Harvard University
For more than 30 years, Dr. Fernandes has been involved in
technical and strategic management of both early and late stage
drug development of both recombinant-derived biologicals and of
small molecules.
Dr. Fernandes was, till recently, Vice-President, Pharmaceutical
Development, US/EU Operations for Santen, Inc. of Osaka, Japan, and
prior to that Vice-President and Director of Process Development
and Strategy at Chiron Corporation.
Dr. Fernandes holds a Ph.D. and M.S. in Chemical and Biochemical
Engineering, from Rutgers University. He has authored several
publications and holds miscellaneous patents in this field.
Viropro further announces it has retained the services of Jones
Day of Washington DC as its outside legal counsel.
Finally, unaudited financial statements for Viropro have been
produced and will be audited during the coming weeks. These
financials will consolidate Biologics Process Development Inc.
figures starting from April 1st 2010.
About Viropro, Inc.:
Viropro, Inc. conducts operations through its subsidiaries
Viropro International Inc., Biologics Process Development, Inc. and
Alpha Biologics Sdn. Bhd. Viropro specializes in the transfer of
its technologies for industrial production of biopharmaceutical
therapeutic proteins for the treatment of various diseases
including cancer, diabetes, hepatitis and multiple sclerosis. The
Company’s principal objective is to provide its high-yield
manufacturing process technology to biopharmaceutical companies in
global markets with unmet medical and/or market needs.
(www.viropro.com)
Viropro Inc. Safe Harbor Statement
Except for any purely historic statements contained herein, the
matters discussed in this press release contain forward-looking
statements that involve risks and uncertainties, which are subject
to section 27A of the Securities Act of 1933, as amended, and
section 21E of the Exchange Act of 1934, as amended, and are
subject to safe harbor created by these sections. Any statements
that express or involve discussions with respect to predictions,
beliefs, plans, projections, objectives, and goals, assumptions of
future events or performances are not statements of purely
historical fact and may be "forward-looking statements".
Forward-looking statements in this release may be identified
through the use of such words such as "expects", "anticipates",
"estimates", "believes", or words of similar import or statements
indicating certain actions that "may", "could", or "might" occur.
All forward-looking statements included in this press release are
based upon information available to Viropro as of the date of this
press release, and Viropro assumes no obligation to update any
forward-looking statements. Actual results, performance or
achievements could differ materially from those anticipated in such
forward-looking statements, which involve numerous risks and
uncertainties. These risks include, without limitation, the
Company's ability to market its products and services in a
competitive environment as well as other factors.
Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
From Oct 2023 to Oct 2024
